Cancer Family
Malignant Nervous System Neoplasm
CI-CAN-00000246Explore in graph →
953 active trials7 approved drugs131 evidence items
- NCIt
- C4788
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000246Explore in graph →
Clinical trials
3,457 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (495)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07833657 | Combined Intrathecal and Systemic Therapy With Trastuzumab Rezetecan for Leptomeningeal Metastases(ITST-ADC-LM) | not yet recruiting | Phase 2 | 28 | Jiuda ZhaoOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT03223103 | Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma | active not recruiting | Phase 1 | 13 | Adilia HormigoOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT03698994 | Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) | active not recruiting | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 2 | Sep 21, 2026 | clinicaltrials |
| NCT04977375 | Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma | recruiting | Phase 1 / Phase 2 | 10 | Chirag G. PatilOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06176989 | Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors | recruiting | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06804655 | Pharmacoscopy for Patients With Refractory Primary Brain Tumors(EViDENCE-BT) | recruiting | Phase 2 | 40 | University of ZurichOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06838676 | ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas | recruiting | Phase 2 | 60 | Nationwide Children's HospitalOTHER | 5 | Sep 21, 2026 | clinicaltrials |
| NCT07831161 | Safety and Efficacy of Autologous Natural Killer Cell Therapy (CHANK-101) in Patients With Recurrent Glioblastoma | not yet recruiting | N/A | 60 | Dong-A University HospitalOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07831187 | Entacapone Plus Bevacizumab for Glioblastoma at First Recurrence | not yet recruiting | Phase 1 / Phase 2 | 96 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07831369 | VISTA: Valproic Acid, Irinotecan, and Simvastatin for Recurrent Glioma | recruiting | Phase 2 | 52 | Inova Health Care ServicesOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07831772 | REMIND Maintenance Radiotherapy for Newly Diagnosed Glioblastoma(REMIND) | recruiting | N/A | 4 | University of MinnesotaOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT03587038 | OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy for Newly Diagnosed Glioblastoma | active not recruiting | Phase 1 | 27 | University of OklahomaOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT05077735 | Stereotactic Biopsy Split-Course Radiation Therapy in Diffuse Midline Glioma, SPORT-DMG Trial | active not recruiting | Phase 2 | 17 | Mayo ClinicOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07089641 | ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial | recruiting | Phase 1 | 50 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07298083 | DoD Award NF230020 Identification of Metabolic Markers and Statistical Prediction of MPNST for Rapid Diagnosis and Assessment of Surgical Margins | recruiting | — | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07827001 | PilotStudyAssessSafeActiveSurveillancApproachLocalThe Pa w/BrainMetsUndergoinCNSPenetratSystemicThe | recruiting | — | 12 | University of California, IrvineOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT05421897 | Rapid Administration Pilot for Infusing Dinutuximab(RAPID) | active not recruiting | Phase 2 | 30 | Children's Hospital Los AngelesOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT06395103 | Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) | recruiting | Phase 1 / Phase 2 | 90 | Merck Sharp & Dohme LLCINDUSTRY | 23 | Sep 17, 2026 | clinicaltrials |
| NCT06816927 | Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab(GIANT) | recruiting | Phase 2 | 92 | Duke UniversityOTHER | 2 | Sep 17, 2026 | clinicaltrials |
| NCT02974738 | A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001) | active not recruiting | Phase 1 | 120 | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 0 | Sep 16, 2026 | clinicaltrials |
| NCT03535350 | Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma | active not recruiting | Phase 1 | 36 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT04211675 | NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab(STING) | active not recruiting | Phase 1 / Phase 2 | 31 | Nationwide Children's HospitalOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT04462328 | Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma | active not recruiting | Phase 1 | 25 | Washington University School of MedicineOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT02974621 | Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma | active not recruiting | Phase 2 | 70 | National Cancer Institute (NCI)NIH | 1 | Sep 15, 2026 | clinicaltrials |
| NCT03115333 | DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma | active not recruiting | N/A | 146 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 15, 2026 | clinicaltrials |
| NCT05495295 | First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Advanced Solid Tumours(PhAST) | active not recruiting | Phase 1 | 149 | Phost'In TherapeuticsINDUSTRY | 2 | Sep 15, 2026 | clinicaltrials |
| NCT05535166 | Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma | recruiting | Phase 2 | 130 | St. Jude Children's Research HospitalOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06132438 | Immunotherapy Targeting of Cytomegalovirus Antigens in Glioblastoma | recruiting | Phase 1 | 26 | Charlotte LemechOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06357377 | A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors | recruiting | Phase 1 | 12 | Neonc Technologies, Inc.INDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07389278 | Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG) | not yet recruiting | Phase 1 / Phase 2 | 97 | Sabine Mueller, MD, PhDOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07819838 | Testing the Addition of an Anti-Cancer Drug, Daraxonrasib, for Relapsed or Refractory Solid Tumors With RAS Mutations | not yet recruiting | Phase 1 / Phase 2 | 77 | Children's Oncology GroupNETWORK | 0 | Sep 15, 2026 | clinicaltrials |
| NCT02704858 | Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma | active not recruiting | Phase 1 / Phase 2 | 49 | Neonc Technologies, Inc.INDUSTRY | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04771806 | Serial Advanced Magnetic Resonance Imaging Scan for Guidance of Personalized Adaptive Radiotherapy for High Grade Glioma | recruiting | — | 80 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT05698524 | A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma | recruiting | Phase 1 | 24 | University of NebraskaOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06674811 | Biomarkers of Resiliency In Childhood Cancer Surgery(BRICCS) | recruiting | — | 40 | Mayo ClinicOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06797661 | Insights Into the Pathophysiology of Neurovascular Uncoupling in Patients With Brain Lesions.(NVUCVR) | recruiting | N/A | 40 | Erasme University HospitalOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04870944 | CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma | recruiting | Phase 1 / Phase 2 | 63 | Children's Oncology GroupNETWORK | 2 | Sep 11, 2026 | clinicaltrials |
| NCT07087002 | GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults | recruiting | Phase 1 | 18 | Stanford UniversityOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT05052957 | hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)(hSTAR GBM) | recruiting | Phase 2 | 16 | Leland MethenyOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07349693 | Comparison of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma(Cerebraca-02/3) | not yet recruiting | Phase 2 / Phase 3 | 175 | Everfront Biotech Co., Ltd.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07452458 | Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma | recruiting | Phase 3 | 398 | NRG OncologyOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07811297 | A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers | not yet recruiting | Phase 1 / Phase 2 | 138 | Advenchen Pharmaceuticals, LLC.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT03212274 | Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations | active not recruiting | Phase 2 | 89 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2026 | clinicaltrials |
| NCT04899908 | Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases | recruiting | Phase 2 | 134 | Brigham and Women's HospitalOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT05139056 | Multiple Intracerebral Doses of Neural Stem Cell-Based Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas | recruiting | Phase 1 | 36 | City of Hope Medical CenterOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06410248 | Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma | recruiting | Phase 1 | 22 | Northwestern UniversityOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06613841 | Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of Glioblastoma(GBM) | recruiting | Early Phase 1 | 15 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06934889 | Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma | recruiting | Phase 1 | 60 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06946680 | IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Newly Diagnosed and Recurrent Pediatric High-grade Glioma (pHGG) and Newly Diagnosed Diffuse Intrinsic Pontine Glioma (ndDIPG)(Peds IMPACT) | not yet recruiting | Phase 1 | 24 | University of FloridaOTHER | 1 | Sep 9, 2026 | clinicaltrials |
Data updated 5 days agoSource updated Sep 22, 2026source: clinicaltrials